Updated Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment in 65 Years and Older with CLL

Updated Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment in 65 Years and Older with CLL

User Photo
ASHReport

4 years
434 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Paul Barr, MD of University of Rochester, gives an overview of a clinical trial, Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, that was presented at the 58th ASH Annual Meeting in San Diego, CA.
Up Next Autoplay
>